165 related articles for article (PubMed ID: 26323364)
1. Picropodophyllin inhibits the growth of Ewing's sarcoma cells through the insulin‑like growth factor‑1 receptor/Akt signaling pathway.
Wu YT; Wang BJ; Miao SW; Gao JJ
Mol Med Rep; 2015 Nov; 12(5):7045-50. PubMed ID: 26323364
[TBL] [Abstract][Full Text] [Related]
2. Picropodophyllin inhibits proliferation and survival of diffuse large B-cell lymphoma cells.
Strömberg T; Feng X; Delforoush M; Berglund M; Lin Y; Axelson M; Larsson O; Georgii-Hemming P; Lennartsson J; Enblad G
Med Oncol; 2015 Jul; 32(7):188. PubMed ID: 26021470
[TBL] [Abstract][Full Text] [Related]
3. The cyclolignan picropodophyllin attenuates intimal hyperplasia after rat carotid balloon injury by blocking insulin-like growth factor-1 receptor signaling.
Razuvaev A; Henderson B; Girnita L; Larsson O; Axelson M; Hedin U; Roy J
J Vasc Surg; 2007 Jul; 46(1):108-15. PubMed ID: 17606126
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
[TBL] [Abstract][Full Text] [Related]
6. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.
Huang HJ; Angelo LS; Rodon J; Sun M; Kuenkele KP; Parsons HA; Trent JC; Kurzrock R
PLoS One; 2011; 6(10):e26060. PubMed ID: 22022506
[TBL] [Abstract][Full Text] [Related]
7. Picropodophyllin inhibits tumor growth of human nasopharyngeal carcinoma in a mouse model.
Yin SC; Guo W; Tao ZZ
Biochem Biophys Res Commun; 2013 Sep; 439(1):1-5. PubMed ID: 23973483
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin.
Vasilcanu R; Vasilcanu D; Sehat B; Yin S; Girnita A; Axelson M; Girnita L
Mol Pharmacol; 2008 Mar; 73(3):930-9. PubMed ID: 18070930
[TBL] [Abstract][Full Text] [Related]
9. Picropodophyllin inhibits type I endometrial cancer cell proliferation via disruption of the PI3K/Akt pathway.
Dong L; Du M; Lv Q
Acta Biochim Biophys Sin (Shanghai); 2019 Jul; 51(7):753-760. PubMed ID: 31168597
[TBL] [Abstract][Full Text] [Related]
10. MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway.
Li J; You T; Jing J
Cell Prolif; 2014 Apr; 47(2):152-60. PubMed ID: 24517182
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide inhibits Ewing's sarcoma cell invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase.
Zhang S; Guo W; Ren TT; Lu XC; Tang GQ; Zhao FL
Anticancer Drugs; 2012 Jan; 23(1):108-18. PubMed ID: 21946058
[TBL] [Abstract][Full Text] [Related]
12. Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway.
Krishnan K; Bruce B; Hewitt S; Thomas D; Khanna C; Helman LJ
Clin Exp Metastasis; 2006; 23(3-4):227-36. PubMed ID: 17028919
[TBL] [Abstract][Full Text] [Related]
13. Picropodophyllin (PPP) is a potent rhabdomyosarcoma growth inhibitor both in vitro and in vivo.
Tarnowski M; Tkacz M; Zgutka K; Bujak J; Kopytko P; Pawlik A
BMC Cancer; 2017 Aug; 17(1):532. PubMed ID: 28793874
[TBL] [Abstract][Full Text] [Related]
14. Targeting the insulin-like growth factor-1 receptor by picropodophyllin for lung cancer chemoprevention.
Zhang Q; Pan J; Lubet RA; Wang Y; You M
Mol Carcinog; 2015 Jun; 54 Suppl 1():E129-37. PubMed ID: 25163779
[TBL] [Abstract][Full Text] [Related]
15. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
Merchant MS; Woo CW; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
[TBL] [Abstract][Full Text] [Related]
16. The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin.
Wang Q; Wei F; Lv G; Li C; Liu T; Hadjipanayis CG; Zhang G; Hao C; Bellail AC
BMC Cancer; 2013 Nov; 13():521. PubMed ID: 24182354
[TBL] [Abstract][Full Text] [Related]
17. The insulin-like growth factor-I receptor inhibitor picropodophyllin-induced selective apoptosis of hepatocellular carcinoma cell through a caspase-dependent mitochondrial pathway.
E C; Li J; Shao D; Zhang D; Pan Y; Chen L; Zhang X
Oncol Res; 2013; 21(2):103-10. PubMed ID: 24406046
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
Martins AS; Mackintosh C; Martín DH; Campos M; Hernández T; Ordóñez JL; de Alava E
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3532-40. PubMed ID: 16740780
[TBL] [Abstract][Full Text] [Related]
19. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures.
Subbiah V; Naing A; Brown RE; Chen H; Doyle L; LoRusso P; Benjamin R; Anderson P; Kurzrock R
PLoS One; 2011 Apr; 6(4):e18424. PubMed ID: 21494688
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biological significance of hepatoma-derived growth factor in Ewing's sarcoma.
Yang Y; Li H; Zhang F; Shi H; Zhen T; Dai S; Kang L; Liang Y; Wang J; Han A
J Pathol; 2013 Nov; 231(3):323-34. PubMed ID: 23878072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
